Comprehensive review of chromophobe renal cell carcinoma

Rohan Garje; Dean Elhag; Hesham A Yasin; Luna Acharya; Daniel Vaena; Laila Dahmoush

doi:10.1016/j.critrevonc.2021.103287

Back

Comprehensive review of chromophobe renal cell carcinoma

Journal article

Open access

Peer reviewed

Comprehensive review of chromophobe renal cell carcinoma

Rohan Garje, Dean Elhag, Hesham A Yasin, Luna Acharya, Daniel Vaena and Laila Dahmoush

Critical reviews in oncology/hematology, Vol.160, pp.103287-103287

04/2021

DOI: 10.1016/j.critrevonc.2021.103287

PMID: 33753250

Files and links (1)

url

https://doi.org/10.1016/j.critrevonc.2021.103287View

Published (Version of record) Open Access

Abstract

Chromophobe renal cell carcinoma (chRCC) is the third most common type of RCC with distinct biology compared to other kidney cancer subtypes. The heterogeneity between the RCC subtypes is associated with noticeable differences in tumor aggressiveness and risk for the development of metastatic disease. ChRCC is characterized by chromosomal aneuploidy, TP53, PTEN, and mitochondrial gene mutations. Though the therapeutic landscape of clear cell RCC (ccRCC) has significantly evolved over the past decade, limited progress has been seen in chRCC due to its infrequent incidence. In fact, the therapeutic approach for chRCC is often extrapolated from ccRCC treatments or studies that combine several forms of nccRCC subtypes. In the new era of genetic profiling of tumors and targeted therapeutics, this review describes the epidemiology, pathology, molecular characteristics, and current management with ongoing clinical trials for chRCC.

Immunotherapy

Chromophobe renal cell carcinoma

Chromosomal aneuploidy

Mitochondrial gene mutations

Targeted therapy

Details

Title: Subtitle: Comprehensive review of chromophobe renal cell carcinoma
Creators: Rohan Garje - University of Iowa
Dean Elhag - University of Iowa
Hesham A Yasin - University of Iowa
Luna Acharya - University of Iowa
Daniel Vaena - University of Iowa
Laila Dahmoush - University of Iowa
Resource Type: Journal article
Publication Details: Critical reviews in oncology/hematology, Vol.160, pp.103287-103287
DOI: 10.1016/j.critrevonc.2021.103287
PMID: 33753250
NLM abbreviation: Crit Rev Oncol Hematol
ISSN: 1040-8428
eISSN: 1879-0461
Publisher: Elsevier B.V
Grant note: DOI: 10.13039/100008893, name: University of Iowa
Language: English
Date published: 04/2021
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Urology; General Internal Medicine; Internal Medicine
Record Identifier: 9984199920502771

Metrics

13 Record Views

84 Times Cited - Web of Science